In­tel­liphar­ma­ceu­tics shares crushed as FDA ex­perts snub pain drug; Mon­cef Slaoui joins Mod­er­na board

→ Af­ter get­ting chas­tised by reg­u­la­tors in an in­ter­nal FDA re­view of Toron­to-based In­tel­liphar­ma­ceu­tics$IP­CI new pain drug Rex­ista, a pan­el of out­side ex­perts joined in, vot­ing to rec­om­mend a re­jec­tion of the ther­a­py. Billed as a new ver­sion of oxy with new fea­tures which the biotech claimed would de­ter abuse, the pan­elists vot­ed 22 to 1 against an OK. And all of them agreed that the com­pa­ny nev­er of­fered the da­ta that would be need­ed to gain an abuse-de­ter­rent note on the la­bel, if it were to be ap­proved. The com­pa­ny’s shares cratered, drop­ping 45%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.